Video wird geladen...

Video konnte nicht geladen werden

Zur Startseite

STUDY: Advanced Alzheimer’s patient who could barely speak RAPIDLY REGAINED speech, memory, and bladder control after ONE psilocybin dose. She REMAINED functionally improved for AT LEAST a month. In preclinical studies, a single psilocybin dose increased neuronal dendritic-spine density and size in the frontal cortex by ~10% within 24...

82,177 Aufrufe • vor 1 Monat •via X (Twitter)

0 Kommentare

Keine Kommentare verfügbar

Kommentare vom Original-Post werden hier angezeigt

Ähnliche Videos

Massive Study Reveals More Bad News for the COVID Vaccinated The "conspiracy theorists" were right once again. There are HUGE health risks from the jab, no matter how much the media tries to downplay it. Take a look for yourself: Moderna (Dose 1/2): • Swelling of the brain and spinal cord: Almost 4 times (400%) increased risk (first dose) • Myocarditis: 3.48 times increased risk (first dose) • Pericarditis: 1.74 times increased risk (first dose) • Myocarditis (Second shot): 6.1 times increased risk AstraZeneca: • Blood clots: 3.23 times (320%) increased risk • Guillain–Barré syndrome (could lead to paralysis): 2.49 times increased risk • Pericarditis (Third dose): 6.91 times increased risk Pfizer: • Myocarditis (First dose): 2.78 times increased risk • Myocarditis (Second dose): 2.86 times increased risk • Myocarditis (Third dose): 2.09 times increased risk Moderna (Further doses beyond the first): • Myocarditis from the second shot: 6.1 times increased risk • Pericarditis (Fourth dose): 2.64 times increased risk • Myocarditis from the third dose: 2.01 times increased risk This study conducted by the Global Vaccine Data Network (GVDN) looked at a cohort of 99 million vaccinated individuals. The increased risks were compared to what was expected based on pre-COVID-19 vaccination healthcare data, or in simpler terms, if you did not receive the jab at all. Most of the above risk factors are calculated based on a single dose. When you consider many people took three shots or more, the results of the study become even more alarming. Listen to what Del Bigtree, host of The Highwire, had to say: “And they’re not even talking about cancer … but how about this? You’re like, well, only six times the amount of myocarditis. But if you add that six times to the two or three times for myocarditis. And what about the blood clots and stroke? What happens? “They’re not just six by themselves. They all stack up. What are we, like, 20 times the amount of risk for getting totally jacked up by this vaccine? And they’re only just starting the list. “And trust me, the scientists did everything they could to make this as conservative as they possibly could because no one wants to be responsible for, God forbid, say, we need to recall a vaccine.”

The Vigilant Fox 🦊

809,984 Aufrufe • vor 2 Jahren

She was 41, had Down syndrome and full-blown Alzheimer’s. In her entire life, she had NEVER spoken a three-syllable word. The longest thing she could say was “Mom-ma”. Then her mother put her on a strictly measured ketogenic diet. Three weeks later — 21 days — she looked at her mom in church, smiled, and clearly said: “I understand.” Her mother, who had cared for her every single day for 41 years, broke down in tears in the doctor’s office. She had never heard her daughter string three syllables together. Ever. This is a real patient story told by Dr. Annette Bosworth on Steven Bartlett’s Diary of a CEO. The same patient lost another 20 lbs, started doing household jobs again, left the house willingly, and — according to her lifelong caregiver — had the best brain function her mom had ever witnessed. This is NOT medical advice. This is NOT a claim that keto cures Alzheimer’s (it doesn’t — yet). This is one extraordinary anecdote that lines up with what scientists are seeing in early research: - Alzheimer’s brains struggle to burn glucose (“Type 3 diabetes”) - Ketones bypass that defect and fuel the brain more efficiently - Small human studies show temporary memory & cognition improvements in mild Alzheimer’s - Bigger, longer trials are urgently needed But when you watch a mother cry because her daughter spoke a full sentence for the first time at age 41… …it’s hard not to feel something massive is being uncovered. Watch the 4-minute clip. This is the kind of story that should make researchers run, not walk, to the lab. Important: This is an individual case. Results are not typical. Ketogenic diets carry risks and are not suitable for everyone. Always consult your doctor before making major dietary changes, especially with neurological conditions.

Camus

1,470,436 Aufrufe • vor 9 Monaten

"Ivermectin's Miraculous Results For Neurological Conditions Of Parkinson's & Alzheimer's." Dr William Makis Buried Research, Deleted From Google, Has Been Found, Proving Ivermectin Reverses Alzheimer's. Neurological Disease Improves In Only A Few Days On Ivermectin Therapy... Dementia affects more than 55 million people globally, with Alzheimer’s disease (AD) being the most prevalent subtype. These neurodegenerative disorders, including debilitating Parkinson's Disease, progressively impairs memory, cognition, daily functioning, muscle & body control. As interest grows in repositioning known compounds for neurodegenerative applications, ivermectin—a macrocyclic lactone with FDA-approved antiparasitic use—has surfaced as a candidate for neurological disease therapy. Deleted Research Study That Google Scrubbed... I Found It Last Week After Hours Of Research. Here Is A Paraphrased Summary In 'Non Scientific' Regular Language: 70 male Wistar rats were used in the research study. At baseline the rats had cognitive ability to do a task session at the rate of 2.8 minutes with 1.3 errors. Alzheimer's Disease (AD) was induced by injecting them with ALUMINUM CHLORIDE until their cognitive ability to do the same task session regressed to the slow rate of 6.5 minutes with 4.4 errors. These rats were then given IVERMECTIN for 4 consecutive weeks. The same task session improved drastically from 6.5 minutes back to only 3.6 minutes. And the rate of errors improved from 4.4 back to only 1.4 errors. Almost back to baseline in only 4 weeks at 3.6 minutes with 1.4 errors. Recent studies have explored its effects on neuroinflammation, neurotransmission & synaptic protection. Ivermectin’s Effects On Neurological Disease: 1. Anti-Inflammatory Effects: A 2023 study published in Inflammation demonstrated that ivermectin mitigates neuroinflammatory damage in encephalomyelitis. Ivermectin reduced inflammatory cytokines. 2. Stabilizes Neurotransmission: A 2019 study in PLOS Pathogens found that ivermectin restores balance in synaptic neuro pathways. 3. Cholinergic Transmission: A 2024 study published in Cell & Bioscience reported that ivermectin increased activity of striatal cholinergic interneurons, enhancing dopamine release via nicotinic receptor modulation. Conclusion: Ivermectin is emerging as more than an antiparasitic agent. Its anti-inflammatory, synaptic & cholinergic effects are beneficial in neurodegenerative disorders like Dementia, Alzheimer's & Parkinson's. Dosages suggested by Dr William Makis: Parkinson’s: Patients on high-dose ivermectin (60-72mg) saw dramatic improvements in movement & symptoms. - Multiple cases of symptom reversal—where tremors, stiffness & rigidity significantly improved. Alzheimer’s: Patients on low-dose ivermectin (12-24 mg for 4-5 days) brought back memories, recognition & cognitive function in patients. Why Isn’t This Everywhere? - A preclinical Alzheimer’s study proving ivermectin’s healing ability was SCRUBBED from Google. - Big Pharma doesn’t profit from a safe, cheap, Nobel Prize-winning drug that reverses neurodegeneration. This isn’t theoretical—it’s happening NOW in real patients. Decades of suffering could be reversed by a few pills. If you have a loved one with Parkinson’s or Alzheimer’s—TRY IT. The results could be LIFE-CHANGING. 👇Ivermectin Reverses Alzheimer's (Deleted Study)👇 👇Ivermectin For Autoimmune & Neurological Ills👇 👇Ivermectin Increases Choline & Dopamine👇 Speaker: Dr William Makis, Nuclear Medicine Physician & Cancer Researcher

Valerie Anne Smith

636,705 Aufrufe • vor 1 Jahr

Largest Vaccine Study Ever Reveals What the "Conspiracy Theorists" Said All Along Scientists found MASSIVE increased risks of developing several serious health conditions post-jab. But headlines suggest they're "small" and "rare." Take a look for yourself. Moderna (1st Dose): • Swelling of the brain and spinal cord: Almost 4 times (400%) increased risk • Myocarditis: 3.48 times increased risk • Pericarditis: 1.74 times increased risk • Myocarditis (Second shot): 6.1 times increased risk AstraZeneca: • Blood clots: 3.23 times (320%) increased risk • Guillain–Barré syndrome (could lead to paralysis): 2.49 times increased risk • Pericarditis (Third dose): 6.91 times increased risk Pfizer: • Myocarditis (First dose): 2.78 times increased risk • Myocarditis (Second dose): 2.86 times increased risk • Myocarditis (Third dose): 2.09 times increased risk Moderna (Further doses beyond the first): • Myocarditis from the second shot: 6.1 times increased risk • Pericarditis (Fourth dose): 2.64 times increased risk • Myocarditis from the third dose: 2.01 times increased risk This study conducted by the Global Vaccine Data Network (GVDN) looked at a cohort of 99 million vaccinated individuals. The increased risks were compared to what was expected based on pre-COVID-19 vaccination healthcare data, or in simpler terms, if you did not receive the jab at all. Most of the above risk factors are calculated based on a single dose. When you consider many people took three shots or more, the results of the study become even more alarming. Listen to what Del Bigtree had to say: "You're like, well, only six times the amount of myocarditis. But if you add that six times to the two or three times for myocarditis. And what about the blood clots and stroke? What happens? "They're not just six by themselves. They all stack up. What are we, like, 20 times the amount of risk for getting totally jacked up by this vaccine? And they're only just starting the list. "And trust me, the scientists did everything they could to make this as conservative as they possibly could because no one wants to be responsible for, God forbid, say, we need to recall a vaccine."

The Vigilant Fox 🦊

523,940 Aufrufe • vor 2 Jahren

There is now converging evidence in animals and humans that omega-3 fatty acids are at the least anti-catabolic and, likely, anabolic. They seem to do this by shifting the balance away from breakdown and more towards muscle building, particularly in the context of anabolic resistance. Animal studies show omega-3 fatty acids augment muscle development: Steers fed omega-3s showed improved amino acid efficiency and activated pathways involved in muscle growth. Similarly, pigs given a high omega-3 diet exhibited larger muscles and markers of improved amino acid absorption and use. But more importantly, we have human evidence: • In one study, young women taking 5 grams of omega-3s per day cut their muscle loss almost in half and increased muscle protein synthesis after two weeks of leg immobilization. • In another study, older adults consuming 3.36 grams of omega-3s daily for two months had an increase in muscle protein synthesis in the presence of amino acids and insulin. • Yet another study found that healthy older adults taking 4 grams of omega-3s daily for half a year increased various measures of muscle size and strength. • Still another study, older adults who consumed 4 grams of krill oil daily for six months improved knee strength, grip strength, thigh muscle thickness, and measures of muscle nerve response. There are still open questions. For example, a consistent theme is that many of the studies are high dose at 4 and 5 grams per day - does that imply that these effects in muscle only happen at high dosages? Another question we might ask is, in what context is omega-3 more anabolic - for example, in old age? During immobilization? When protein intake is sub-optimal for muscle building? (It often is for many of us.) Listen to my recent podcast guest Dr. Chris McGlory for more discussion of this fascinating new emerging field. Show notes and transcript for this episode here:

Dr. Rhonda Patrick

190,965 Aufrufe • vor 3 Jahren

Today we’re reporting interim Phase 1 clinical data for our REC-617 monotherapy trial – with plans to expand into combination studies in advanced solid tumors. At the AACR Special Conference in Cancer Research, CSO David Hallett shared interim monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumors. 🔹The interim Phase 1 clinical data for REC-617 included: ▫️Dose-linear pharmacokinetics (PK) with rapid absorption and robust pharmacodynamic (PD) biomarker modulation, suggesting substantial target engagement; ▫️Confirmed partial response (PR) during monotherapy dose-escalation in a patient with platinum-resistant ovarian cancer, treated with 4 lines of prior therapy in an advanced setting, with durable response ongoing after more than 6 months of treatment; ▫️In 4 additional patients, a best response of stable disease (SD) for up to 6 months of treatment. Dr. Hallett noted: “Cell cycle dysregulation and transcriptional 'addiction' are both hallmarks of many aggressive cancers. By inhibiting CDK7, we have the potential to target both mechanisms while fine tuning the therapeutic index.” "These initial findings for REC-617 represent an exciting step forward in the development of CDK7 inhibitors, with a favorable PK/PD profile and a durable confirmed partial response observed in dose escalation in a highly pre-treated patient population," said Najat Khan, Ph.D., Chief R&D Officer and Chief Commercial Officer. “Designed using our AI-powered OS platform, REC-617 reflects our focus on enhancing the therapeutic index to deliver more effective and safer treatment options for patients. We are eager to continue this momentum in dose escalation and to initiate the next phase of the program next year." 👉Learn more: 🔹Join the Update Call: Tomorrow, Tues., Dec. 10 at 8:30am ET, Dr. Hallett and Dr. Khan will hold a live Update Call webcast to present the preliminary data. ▫️Submit questions for the Update Call here: ▫️Tune in to the Update Call here on X or on: LinkedIn: YouTube:

Recursion

11,893 Aufrufe • vor 1 Jahr

After a year of intensive research, Dr. William Makis presents the most crucial graph of his career: the ivermectin dosing schedule for cancer. Dr. Makis recommends a starting dose of 1mg per kg of body weight per day for most cancers, including breast, colon, lung, pancreatic, renal, gastric, and leukemias. For a 60kg individual, this translates to 60mg daily, which can be taken as: - Five 12mg pills - Or 6ml of liquid (approximately one teaspoon plus 1ml) The evidence supporting the efficacy of ivermectin is compelling and dose-dependent. - Dr. Shankara Chetty observed a significant drop in a prostate cancer patient’s PSA from 89 to 11 after taking 45mg/day. - Dr. Tess Lawry’s case study showed a remarkable decrease in CA125 (an ovarian cancer marker) from 288 to 22 after just 0.2mg/kg. - A long-term Castro study on children with leukemia demonstrated no side effects after 6 months at a dose of 1mg/kg. For aggressive cancers like pancreatic and brain cancers, a higher dose may be necessary due to the blood-brain barrier. Dr. Makis cites examples: - Dr. Landrito’s colleague with terminal gallbladder cancer experienced the disappearance of cancer after 14 months at a dose of 2mg/kg/day. - The highest documented dose is 2.5mg/kg, as reported by Dr. Chetty, with only transient visual side effects that resolved. Mainstream oncology is unlikely to offer this treatment due to ivermectin’s generic, off-patent status and unprofitable nature. Consequently, there are no funded clinical trials. Dr. Makis concludes that using ivermectin in cancer treatment is straightforward and highly safe. He strongly suggests that those struggling with cancer should start with a dose of 1mg/kg/day. This can be taken for several months, even over a year, with an excellent safety profile based on long-term anecdotal evidence. The power to fight cancer may already be within your reach.

Commentary | Global Ivermectin Research Hub

102,157 Aufrufe • vor 5 Monaten

A stunning revelation from the front lines of medicine. Dr. William Makis is reporting unprecedented success using ivermectin for two of our most devastating neurological conditions: Parkinson's and Alzheimer's disease. His accidental discovery is yielding results that defy conventional expectations. For Parkinson's, high-dose ivermectin (60-72mg) is facilitating remarkable recoveries. Patients on maximum standard treatments, once barely mobile, are now experiencing dramatic improvements in movement and symptoms. One such patient, after a few weeks of treatment, returned to playing golf—an activity lost for years. The outcomes in Alzheimer's are even more profound. Dr. Makis details how family members, following his protocol of low-dose ivermectin (12-24mg for a few days), are witnessing what can only be described as medical miracles. Loved ones who had not recognized family members for years are suddenly reconnecting. Memories are flooding back; cognitive abilities are being restored. In one extraordinary case, a patient was taken off hospice after their condition improved so drastically. The stories are heart-rending: "My grandma's back." Families are reclaiming precious time with loved ones they felt they had lost forever. All from a few pills of a medication with a well-established safety profile. Dr. Makis challenges the medical establishment, noting that supportive preclinical research on ivermectin and Alzheimer's appears to have been scrubbed from mainstream search engines, a silent testament to the battle over this repurposed drug. He urges the public to look at the evidence he shares on his platforms. The potential for a safe, accessible, and effective treatment for these neurodegenerative scourges is too significant to ignore. The question remains: When the evidence is this compelling, and the reward is the reversal of human suffering, why isn't this being researched at the highest levels?

Camus

711,397 Aufrufe • vor 11 Monaten

I am currently fundraising to build the pharma company of the future. Please email me at [email protected] if you are interested (angel checks + VC welcome). Advances in AI + robotics now enable a ‘single’ human operator to carry out the entire scientific discovery process for a new drug, while costing orders of magnitude less than usual. As proof, I developed two new drugs by myself, with zero outside investment, and assistance only from frontier AI models and liquid-handling robotics. PAC-832 is the world’s first selective GalR1 antagonist for Alzheimer’s disease. PAC-3310 is a new selective M4 agonist for schizophrenia, improving on the selectivity profile of the breakthrough drug Cobenfry (which spearheaded the $14B acquisition of its developer Karuna Therapeutics). This level of efficiency is unprecedented and will enable me to generate >40x more clinical-stage drugs (per dollar spent) than a typical pharma company. Pfizer currently has the most clinical-stage drugs at 137. I will be able to reach 10 clinical-stage drugs within 2 years, then surpass Pfizer within the next 5 years. This plan is contingent on me optimizing one more set of studies known as ‘IND-enabling studies,’ which are required by international regulations to be done prior to clinical trials. This involves me (1) building out my own GMP drug manufacturing facility in SF, and (2) optimizing GLP toxicity studies, which I will be doing in China for cost reasons. Both these things are critical to keep overall costs low and require significant resources, which is why I need to raise money, but are eminently doable. I expect them to take 1-2 years in total. After that, my optimized drug synthesis-to-clinical testing pipeline will be done, and I will start turning the flywheel. The long-term, hardest, yet most important task will be optimizing the clinical trials themselves. In short, I intend to accomplish this by launching the most comprehensive, worldwide site search campaign that I can muster. Once the clinical trials are optimized, then I can finally close the loop on the make -> test -> iterate cycle whose speed dictates progress in drug discovery. The 1950-60s are commonly referred to as the ‘golden age of drug discovery’ due to the large number of transformative medicines that emerged from that era. The key to their success was their tight clinical feedback loop - new drugs were synthesized and rapidly tested in the clinic within 1 year. Today, this process takes 10x as long. Enabled by new technologies like AI and robotics, I strongly believe it is possible to bring back the old level of speed and efficiency. A new golden age of drug discovery is on the horizon, and Pace Pharmaceuticals is its herald.

Douglas Yao

155,594 Aufrufe • vor 1 Tag